Citi Says Moderna Looks Too Expensive After Cancer-Vaccine Rally
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.
Cantor initiates LXRX Overweight with an $8 target on sotagliflozin’s fully enrolled Phase 3 SONATA-HCM trial and a Q1 2027 readout.
The firm points to bempikibart in severe alopecia, a 1H 2027 Phase 3 start, and a stronger cash runway.
Guggenheim named Damora a Best Idea, citing the potential for earlier, longer mCALR treatment to expand the myelofibrosis and essential thrombocythemia markets.
B. Riley rates Precigen Buy on Papzimeos, the first FDA-approved adult RRP therapy, plus Q2 profit and management’s year-end cash break-even goal.
The Glyph pipeline, 2027 catalyst, and cash runway into 2029 drive the case.